...Phase II trial to evaluate continuous IV sevuparin for 2-7 days in about 77 patients. Dilaforette AB...

...FDA granted Orphan Drug designation to sevuparin from Dilaforette to treat sickle cell disease (SCD). Dilaforette...
...to start a Phase II trial of the heparin analog to treat SCD in 1H15. Dilaforette AB...

...Dilaforette will pay Ergomed an undisclosed sum to conduct an international Phase II trial of Dilaforette’s...
...back into Dilaforette, which the companies say represent 30-50% of the cost of the trial. Dilaforette...
...a regulatory strategy. The trial for the heparin analog is expected to begin this half. Dilaforette AB...

...began a double-blind, placebo-controlled, Indian Phase II trial to evaluate sevuparin in about 50 patients. Dilaforette AB...

...health companies Dilafor AB and Umecrine Mood AB ; infectious disease companies Biosergen A/S and Dilaforette AB...
...Biosergen A/S , Trondheim, Norway Clanotech AB , Solna, Sweden Dilafor AB , Solna, Sweden Dilaforette AB...

...The 13 Karolinska companies are Akinion Pharmaceuticals AB , Aprea AB , Axelar AB , Dilaforette AB...

...about 98 patients with uncomplicated falciparum malaria. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Malanil. Dilaforette AB...